Open Orphan PLC (AIM:ORPH, OTC:OPORF)'s CEO, Yamin 'Mo' Khan, joined Proactive London's Chris Rhodes with news of a new flu contract trial with one of its current big pharma clients.
This study, the third undertaken with this client, is a full 'end-to-end ' contract and will involve a new challenge agent with the majority of the revenue coming through in 2023.
Open Orphan has now won repeat business with four of the world's top ten big pharma companies, he says, and reflects its leading market position in challenge trial research.